948571-47-9

Basic information

• Product Name: 2-(4-AMino-1H-pyrazol-1-yl)ethanol
• Synonyms: 2-(4-Amino-1H-pyrazol-1-yl)
• CAS NO: 948571-47-9
• Molecular Formula: C₅H₉N₃O
• Molecular Weight: 127.14446
• Mol File: 948571-47-9.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 337.9±22.0 °C(Predicted)
• Appearance: /
• Density: 1.35±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 14.42±0.10(Predicted)
• CAS DataBase Reference: 2-(4-AMino-1H-pyrazol-1-yl)ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-AMino-1H-pyrazol-1-yl)ethanol(948571-47-9)
• EPA Substance Registry System: 2-(4-AMino-1H-pyrazol-1-yl)ethanol(948571-47-9)

Safety Data

• Hazardous Substances Data: 948571-47-9(Hazardous Substances Data)

Usage

General Description

2-(4-Amino-1H-pyrazol-1-yl)ethanol is a chemical compound that belongs to the class of ethanolamines. It is a derivative of pyrazole, a heterocyclic organic compound. This chemical has a molecular formula C4H7N3O, with the structural formula CH3CHOHCH2NHCH2NH2. 2-(4-Amino-1H-pyrazol-1-yl)ethanol has been studied for its potential pharmaceutical applications, such as its ability to act as an anticonvulsant and its potential use in the treatment of neurological disorders. It is also used in chemical research and as a reagent in organic synthesis. However, the compound may pose hazards to human health and the environment, and proper safety precautions must be taken when handling it.

Upstream product

• 2075-46-9 4-nitro-1H-pyrazole 
• 540-51-2 2-bromoethanol 
• 42027-81-6 1-β-hysroxyethyl-4-nitropyrazole 

Downstream Products

• 1394162-44-7 2-(4-(5-(m-tolyl)oxazole-4-carboxamido)-1H-pyrazol-1-yl)ethyl methanesulfonate 
• 1394162-45-8 2-(4-(5-(m-tolyl)oxazole-4-carboxamido)-1H-pyrazol-1-yl)ethyl 4-methyl-benzenesulfonate 
• 1394161-09-1 5-m-tolyl-oxazole-4-carboxylic acid {1-[2-(benzo[1,3]dioxol-5-yloxy)-ethyl]-1H-pyrazol-4-yl}-amide 
• 1394161-75-1 5-m-tolyl-oxazole-4-carboxylic acid {1-[2-(4,6-dimethoxy-pyrimidin-2-yloxy)-ethyl]-1H-pyrazol-4-yl}-amide 
• 1394162-42-5 N-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-5-(m-tolyl)oxazole-4-carboxamide 
• 1403894-06-3 2-(4-(7-(2-fluorobenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-1H-pyrazol-1-yl)ethanol 
• 1421856-75-8 C₂₂H₂₁F₂N₇O₃ 
• 1429297-41-5 C₂₀H₁₉Cl₂FN₄O₄ 
• 1453210-35-9 2-[4-({5-[(2-fluoro-3,5-dimethoxybenzyl)oxy]pyrimidin-2-yl}amino)-1H-pyrazol-1-yl]ethanol 
• 1453208-66-6 2-[4-({5-[(2,6-difluoro-3,5-dimethoxybenzyl)oxy]pyrimidin-2-yl}amino)-1H-pyrazol-1-yl]ethanol 
• 1453212-89-9 tert-butyl 4-{2-[4-({5-[(2,6-difluoro-3,5-dimethoxybenzyl)oxy]pyrimidin-2-yl}amino)-1H-pyrazol-1-yl]ethyl}piperazine-1-carboxylate 
• 1453212-32-2 2-[4-({5-[(2,6-difluoro-3,5-dimethoxybenzyl)oxy]pyrimidin-2-yl}amino)-1H-pyrazol-1-yl]ethyl methanesulfonate 

Relevant articles and documents

FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

The present disclosure relates to a class of fused pyrimidine compounds of Formula I, their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to a process of preparation of these fused pyrimidine compounds, and to pharmaceutical compositions containing them.

Preparation method and application of novel 6-amino-1H-pyrazolo[3,4-d]pyrimidine JAK kinase inhibitors

The present invention provides drugs used for preventing, treating and/or ameliorating autoimmune diseases (such as psoriasis, rheumatoid arthritis, inflammatory enteritis diseases, Sjogren's syndrome, Behcet's disease, multiple sclerosis and systemic lupus erythematosus). The drugs have excellent JAK kinase inhibitory activity. The present invention also provides pharmaceutically acceptable compositions including the above compounds, and methods for preparing the compounds.

Design, synthesis, and biological evaluation of some novel 4-aminoquinazolines as Pan-PI3K inhibitors

A series of 4-aminoquinazolines derivatives containing hydrophilic group were designed and identified as potent Pan-PI3K inhibitors in this study. The results of antiproliferative assays in vitro showed that this series of compounds had strong inhibition of tumor growth, especially compound 7b for MCF-7 cells but weak inhibition to normal cells. PI3K kinase assay showed that 7b had high activity for three PI3K isoforms with the IC50 values of picomole. The western blot assay indicated that 7b could decrease the phospho-Akt (S473) in a dose-dependent manner. Further experiments showed that 7b could induce apoptosis in MCF-7 cells. Four key hydrogen bonding interactions were found in the docking of 7b with PI3K kinase. All these results suggested that 7b is a potent PI3K inhibitor and could be considered as a potential candidate for the development of anticancer agents.